Europe
Probiodrug AG announced its financial results for the twelve-month period ending December 31, 2018, prepared in accordance with German GAAP and on a voluntary basis, in accordance with IFRS as endorsed by the European Union.
Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Cystic fibrosis drugmaker Vertex was forced to destroy nearly 8,000 packs of its drug Orkambi after the medication had expired before they could be shipped to the United Kingdom due to a contentious pricing fight.
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company’s kidney cancer drug, Tivozanib.
Specialized CRO and Leading Cancer Center to Develop New Panel of Patient-Derived Xenograft (PDX) Models from Patients with Acquired Resistance to Last-Generation Targeted Drugs in Oncology
Epigenomics AG announced the financial results for the year ended December 31, 2018.
Conference call and webcast, March 27, 2019 at 3pm CET (Frankfurt) / 10am EST (New York)
Heidelberg Pharma AG announced that it will present preclinical data on the application of its proprietary ATAC technology platform in the treatment of triple-negative breast cancer at the Annual Meeting of the American Association for Cancer Research 2019.
New cost competitive wafer-to-wafer layer transfer process delivers low power, increased yield and higher interconnection density and speed
PRESS RELEASES